The study by Yang, R., et al. evaluated the potential of Gal-9 inhibition in tumor therapy from a T cell perspective, where the preferential killing of T cells over cancer cells by anti-Gal-9 antibodies might contribute to tumor immune escape (Yang et al., 2021). This evidence concerns the gene LGALS9 and cancer.